4.3 Article

Cardiac Side Effects of Chemotherapy: State of Art and Strategies for a Correct Management

Journal

CURRENT VASCULAR PHARMACOLOGY
Volume 12, Issue 1, Pages 106-116

Publisher

BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/157016111201140327163302

Keywords

Anthracyclines; anti-neoplastic drugs; cancer; cardiotoxicity; chemotherapy; cyclophosphamide; heart failure; fluoropirimidines; oxidative stress; Trastuzumab; taxanes

Funding

  1. A.P.I.C.E. Project

Ask authors/readers for more resources

In recent years, the development of more effective drugs has provided a better prognosis and an increase in life expectancy for patients at all-stages of cancer. On the other hand, the price for the improving effectiveness of therapies against malignant tumors is the development of severe and potentially life-threatening drug reactions. Among these, cardiac toxic effects have recently gained particular attention. The term cardiotoxicity includes many possible pathological manifestations, but the most frequent is the reduction in cardiac function, potentially leading to heart failure and death. Importantly, the development of cardiac dysfunction may occur immediately after drug administration, or after years. The purpose of this review is to discuss the clinical features of cardiotoxicity, its molecular basis and novel possible strategies to reduce the likelihood of serious cardiac complications.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available